PT UBC Medical Indonesia Tbk (IDX:LABS)

Indonesia · Delayed Price · Currency is IDR

121.00

-1.00 (-0.82%)

Nov 5, 2026, 3:39 PM WIB

Market Cap	473.40B -16.2%
Revenue (ttm)	214.40B +21.4%
Net Income	8.73B -6.2%
EPS	2.23 -5.3%
Shares Out	3.91B
PE Ratio	54.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,800
Open	122.00
Previous Close	122.00
Day's Range	121.00 - 124.00
52-Week Range	119.00 - 260.00
Beta	0.05
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 30, 2027

About IDX:LABS

PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provides TB management products, such as Quantiferon TB Hold Plus, Genoschola... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2014

Employees 54

Stock Exchange Indonesia Stock Exchange

Ticker Symbol LABS

Full Company Profile

Financial Performance

In 2025, IDX:LABS's revenue was 199.30 billion, an increase of 34.99% compared to the previous year's 147.64 billion. Earnings were 13.51 billion, an increase of 357.50%.

Financial Statements